Clinical trials for the AstraZeneca vaccine resume

13 September 2020
129 Views

Clinical trials of the coronavirus vaccine by AstraZeneca and the University of Oxford have resumed.

The “green light” was given by the British Health Regulatory Authority, noting that it was now safe for the tests to proceed, the company announced on Saturday.

It is recalled that on Tuesday the company had announced the suspension of the tests, as one of the volunteers who took part had a serious side effect.

Saturday’s statement from AstraZeneca said the independent U.K. investigation into the event has concluded and it advised the Medicines Health Regulatory Authority, Britain’s equivalent of the Food and Drug Administration, that it was safe to resume the trial. The MHRA concurred and gave the green light for the trial to restart.

“The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic,” the spokesperson, Michele Meixell, wrote in an email.

You may be interested

Coronavirus Greece: 358 new cases, 194 in Attica, 73 intubated & 5 fatalities
GREECE
shares10 views
GREECE
shares10 views

Coronavirus Greece: 358 new cases, 194 in Attica, 73 intubated & 5 fatalities

makis - Sep 23, 2020

Greece announced today 358 new cases of the coronavirus in the country, of which 56 are associated with known outbreaks.…

Asteroid to pass closer to earth than the moon’s distance
WORLD
shares20 views
WORLD
shares20 views

Asteroid to pass closer to earth than the moon’s distance

Panos - Sep 23, 2020

A small asteroid discovered on September 18, 2020, from Mt. Lemmon Observatory in Arizona will pass a lot closer than…

Clocks to turn back an hour on October 25
GREECE
shares14 views
GREECE
shares14 views

Clocks to turn back an hour on October 25

Panos - Sep 23, 2020

Daylight savings will take effect on the last Sunday of October, specifically on October 25, meaning at 3 am of…

Leave a Comment

Your email address will not be published.